A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405

A. Inoue, O. Ishimoto, S. Fukumoto, K. Usui, T. Suzuki, H. Yokouchi, M. Maemondo, M. Kanbe, S. Ogura, T. Harada, S. Oizumi, M. Harada, S. Sugawara, T. Fukuhara, T. Nukiwa

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)

Abstract

Background: Amrubicin, a new anthracycline agent, has shown high activity for small-cell lung cancer (SCLC) in previous studies. However, a combination regimen with amrubicin and platinum has been investigated little. On the basis of previous phase I study, we conducted this study to evaluate the efficacy and the safety of amrubicin and carboplatin for elderly patients with SCLC. Methods: Chemotherapy-naive elderly patients with SCLC received amrubicin (35 mg/m2, days 1-3) and carboplatin [area under the curve (AUC) 4.0, day1] every 3 weeks. The primary end point was overall response rate (ORR), and secondary end points were progression-free survival (PFS), overall survival and toxicity profile. Results: From January 2005 to November 2007, 36 patients were enrolled [median age 76 (range 70-83); ECOG performance status of zero and one in 17 and 19 patients, respectively]. One complete response and 31 partial responses were observed (ORR 89%). Median PFS was 5.8 months and median survival time was 18.6 months. Grade 3-4 neutropenia was observed in 97% of the patients and six patients (17%) suffered from grade 3-4 febrile neutropenia. Other toxic effects were moderate and treatment-related death was not observed. Conclusions: Amrubicin combined with carboplatin is quite effective for SCLC with acceptable toxic effects even for the elderly population. Further evaluation of this regimen is warranted.

Original languageEnglish
Pages (from-to)800-803
Number of pages4
JournalAnnals of Oncology
Volume21
Issue number4
DOIs
Publication statusPublished - 2009 Oct 13

Keywords

  • Amrubicin
  • Carboplatin
  • Chemotherapy
  • Elderly
  • Phase II study
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405'. Together they form a unique fingerprint.

Cite this